课题基金 / 基金详情

Ionizing Radiation-Induced DNA damage repair

Ionizing Radiation-Induced DNA damage repair
电离辐射诱导的 DNA 损伤修复
批准号:
10687029
负责人:
Yilun Liu
金额:
$41.8万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2024-08-31

项目摘要

项目成果

Yilun Liu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PARP inhibitors have been used in the clinical treatment for tumors with BRCA1 or BRCA2 mutations. The major function of PARP inhibitors is to suppress PARP1 and PARP2 mediated poly(ADP-ribosyl)ation, a unique posttranslational modification, mainly induced in DNA damage. Suppression of PARylation by PARP inhibitors abolishes early recruitment of DNA damage response factors and impairs DNA damage repair. Because PARylation is a very transient posttranslational modification, normal cells have other repair mechanism to compensate for the loss of PARylation-dependent DNA damage response. However, a set of tumor cells harbor genetic mutations, such as BRCA1/2 mutations, which have already led to impaired DSB repair. With additional PARP inhibitor treatment to abolish PARylation-dependent DNA damage response, these tumor cells will undergo apoptosis. Thus, PARP inhibitor treatment selectively kills tumor cells with DNA damage repair defects, such as BRCA tumors. However, recent clinical trials suggest that only a set of BRCA tumors respond effectively to the PARP inhibitor treatment. Moreover, accumulated evidence indicates that PARP inhibitor treatment is able to suppress the growth of other types of tumor besides BRCA tumors. Thus, to extend the therapeutic potential of PARP inhibitors in cancer treatment, we explored biomarkers for the PARP inhibitor treatment. Interestingly, we found that NADP+, an NAD+ derivative, can suppress the activity of PARPs both in vitro and in vivo. Thus, we hypothesize that NADP+ is an endogenous PARP inhibitor, and the high level of NADP+ in tumor cells is able to sensitize tumor cells for DNA damaging related cancer therapy, including chemotherapy and radiation therapy. In this application, we plan to examine 1) the role of NADP+ in poly(ADP-ribosyl)ation-dependent DNA damage repair; 2) the molecular mechanism that regulates the cellular level of NADP+; 3) the role of NADP+ in sensitizing tumor cells to DNA damaging-associated cancer therapy. Taken together, the proposed study will not only reveal novel molecular mechanism in DNA damage repair, but also identify novel therapeutic approach for cancer treatment.
期刊论文(60)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1158/0008-5472.can-16-2350
发表时间: 2017-01-15
期刊: Cancer research
影响因子: 11.2
作者: [Li M, Chen Q, Yu X]
通讯作者: Yu X
DOI: 10.1101/gad.226357.113
发表时间: 2013-08-15
期刊: Genes & development
影响因子: 10.5
作者: [Li M, Lu LY, Yang CY, Wang S, Yu X]
通讯作者: Yu X
RNF8 deficiency results in neurodegeneration in mice.
RNF8 缺乏导致小鼠神经退行性变
DOI: 10.1016/j.neurobiolaging.2015.07.010
发表时间: 2015-10
期刊: Neurobiology of aging
影响因子: 4.2
作者: [Ouyang S, Song Y, Tian Y, Chen Y, Yu X, Wang D]
通讯作者: Wang D
DOI: 10.3390/cells12162037
发表时间: 2023-08-10
期刊: CELLS
影响因子: 6
作者: [Mo, Chiefe, Shiozaki, Yukari, Omabe, Kenneth, Liu, Yilun]
通讯作者: Liu, Yilun
40
    RECQ5-dependent SUMO2 conjugation of PCNA in the resolution of transcription-replication conflicts
    RECQ5-dependent SUMO2 conjugation of PCNA in the resolution of transcription-replication conflicts
    The function of Topoisomerase I SUMOylation in transcription and chemoresistance
    The function of Topoisomerase I SUMOylation in transcription and chemoresistance
    海外基金